You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥-B(2552.HK)一度暴漲36% 股價創4個月新高
格隆匯 12-21 13:05
格隆匯12月21日丨華領醫藥-B(2552.HK)今日上午盤中一度暴漲36.29%至7.21港元,股價創8月20日以來新高。公司於12月18日公佈,糖尿病用藥多扎格列艾汀(dorzagliatin)第二項III期註冊臨牀研究DAWN(黎明研究,也稱HMM0302)核心結果,顯示出良好安全性和耐受性。結果公佈後,高盛和里昂兩家外資大行齊聲看多。高盛還強調華領醫藥在8月宣佈與拜耳合作後,多扎格列艾汀的商業化進程大大提速,維持買入評級,目標價12.7港元;里昂預期華領醫藥能夠在2022年將成功向市場推出多扎格列艾汀,對其重申買入評級,給出10.34港元的目標價。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account